Strategic Wealth Partners Ltd. Purchases 26,734 Shares of Becton, Dickinson and Company $BDX

Posted by George Bondi on Aug 23rd, 2026

Strategic Wealth Partners Ltd. boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 64.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,186 shares of the medical instruments supplier’s stock after buying an additional 26,734 shares during the period. Strategic Wealth Partners Ltd.’s holdings in Becton, Dickinson and Company were worth $10,319,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of BDX. Auto Owners Insurance Co boosted its position in shares of Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after acquiring an additional 40,528,680 shares in the last quarter. Vanguard Group Inc. raised its position in Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after purchasing an additional 4,223,149 shares in the last quarter. BlackRock Inc. acquired a new position in Becton, Dickinson and Company in the second quarter worth about $3,721,533,000. State Street Corp lifted its stake in Becton, Dickinson and Company by 0.8% during the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock worth $2,714,871,000 after purchasing an additional 116,737 shares during the period. Finally, First Eagle Investment Management LLC boosted its holdings in Becton, Dickinson and Company by 16.5% during the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after purchasing an additional 1,651,592 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $191.95 on Friday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $192.30. The firm has a 50 day moving average of $161.58 and a 200-day moving average of $161.13. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $52.89 billion, a P/E ratio of 57.82, a price-to-earnings-growth ratio of 13.53 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the prior year, the company earned $3.68 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BDX shares. Piper Sandler increased their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research report on Monday, July 6th. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a research note on Friday, August 7th. The Goldman Sachs Group cut their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $185.67.

Get Our Latest Stock Report on BDX

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 11,779 shares of company stock valued at $1,974,669 over the last ninety days. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.